ARCHIVES

Control-Arm CML Patients In Phase III Gleevec Study Allowed To Switch.

This article is from The Cancer Letter archive.

Vol. 28 No. 04 | January 25, 2002

Download PDF Visit The Full Archive

Related Articles

Historical Vs. Current Controls: Comparability, Ethical Issues Argued By Moertel, Freireich

April 20, 1979

NCI Eases Some Cooperative Group Concern; DeVita Considers Other CCOP- Research Base Funding Option

April 2, 1982

Letter In Response To Hadley; RFA Available

July 7, 1995

House Committee Begins Investigation Of NCI’s National Lung Screening Trial.

October 26, 2007

Rituximab After CVP Improves Progression-Free Survival

March 27, 2009

In Brief: Congress Asked To Investigate Dieldrin Danger; Harvard’s Rosenberg To Be NCI Surgery Chief

April 5, 1974